ATOS
Atossa Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
+9/100
Last price
2.45
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
2.45
Day high
2.54
Day low
2.43
Volume
54.63K
Market cap
$24.45M
P/E (TTM)
—
52W range
1.70 – 19.35
Trailing performance
Returnvs SPY
1W
+23.12%
+21.2%
1M
-2.78%
-3.9%
3M
0.00%
-4.5%
6M
-49.80%
-68.0%
YTD
-72.32%
-86.6%
1Y
-83.83%
-100.2%
3Y
-77.93%
-160.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ATOS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
184.22K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 12, 26 | STEINHART RICHARD I Director |
STOCK | 10.00K | $0 | Direct |
| May 12, 26 | CHEN SHU-CHIH Director |
STOCK | 10.00K | $0 | Direct |
| May 12, 26 | GALLI STEPHEN J Director |
STOCK | 10.00K | $0 | Direct |
| May 12, 26 | REMMEL H LAWRENCE Director |
STOCK | 10.00K | $0 | Direct |
| May 12, 26 | FINN JONATHAN F. Director |
STOCK | 10.00K | $0 | Direct |
| May 12, 26 | CIGLER TESSA M.D. Director |
STOCK | 10.00K | $0 | Direct |
| Mar 27, 26 | QUAY STEVEN C Chief Executive Officer |
STOCK | 65.00K | $0 | Direct |
| Mar 26, 26 | DANIEL MARK JAMES CPA Chief Financial Officer |
STOCK | 63.00K | $0 | Direct |
| Jan 20, 26 | QUAY STEVEN C Chief Executive Officer |
— | 325.20K | — | Direct |
| Jan 20, 26 | QUAY STEVEN C Chief Executive Officer |
— | 331.67K | — | Direct |
| May 21, 25 | QUAY STEVEN C Chief Executive Officer |
BUY | 11.24K | $9.89K | Direct |
| Mar 26, 25 | REMMEL H LAWRENCE Director |
BUY | 10.00K | $7.00K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHEN SHU-CHIH |
Director | 11.48K | Stock Award(Grant) |
CIGLER TESSA M.D. |
Director | 10.00K | Stock Award(Grant) |
DANIEL MARK JAMES CPA |
Chief Financial Officer | 63.00K | Stock Award(Grant) |
FINN JONATHAN F. |
Director | 11.67K | Stock Award(Grant) |
GALLI STEPHEN J |
Director | 10.01K | Stock Award(Grant) |
QUAY STEVEN C |
Chief Executive Officer | 89.52K | Stock Award(Grant) |
REMMEL H LAWRENCE |
Director | 10.68K | Stock Award(Grant) |
STEINHART RICHARD I |
Director | 10.00K | Stock Award(Grant) |
Fundamentals
Market cap$24.45M
Enterprise value$-1.64M
Revenue (TTM)—
Gross profit—
EBITDA$-39.23M
Net income$-37.71M
EPS (TTM)$-4.45
Free cash flow$-23.33M
Total cash$26.09M
Total debt$0
Book value / share$2.69
Shares outstanding9.98M
Float9.94M
Short % of float7.64%
Dividend yield0.00%
Beta (5Y)1.28
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.74
PEG ratio—
Price / sales—
Price / book0.91
EV / revenue—
EV / EBITDA0.04
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-89.23%
Return on assets-50.69%
Debt / equity—
Current ratio5.69
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $21.18M | $14.12M | $17.33M | $15.08M | +50.1% |
| Selling, general & admin | $15.96M | $13.50M | $14.04M | $12.61M | +18.2% |
| Total operating expense | $37.14M | $27.62M | $31.38M | $27.69M | +34.5% |
| Operating income | -$37.14M | -$27.62M | -$31.38M | -$27.69M | -34.5% |
| Net interest income | $2.38M | $4.05M | $4.34M | $877.00K | -41.3% |
| Pre-tax income | -$34.77M | -$25.50M | -$30.09M | -$26.96M | -36.3% |
| Tax provision | $0 | $0 | $0 | $0 | — |
| Net income | -$34.77M | -$25.50M | -$30.09M | -$26.96M | -36.3% |
| Net income to common | -$34.77M | -$25.50M | -$30.09M | -$26.96M | -36.3% |
| Basic EPS | -4.04 | -3.04 | -3.60 | -3.15 | -32.9% |
| Diluted EPS | -4.04 | -3.04 | -3.60 | -3.15 | -32.9% |
| EBIT | -$37.14M | -$27.62M | -$31.38M | -$27.69M | -34.5% |
| EBITDA | -$37.13M | -$27.60M | -$31.35M | -$27.68M | -34.5% |
| Basic shares | 8.61M | 8.39M | 8.41M | 8.44M | +2.6% |
| Diluted shares | 8.61M | 8.39M | 8.41M | 8.44M | +2.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $41.30M | $71.08M | $88.46M | $110.89M | — | -41.9% |
| Cash & short-term investments | $41.30M | $71.08M | $88.46M | $110.89M | — | -41.9% |
| Total current assets | $45.62M | $74.46M | $92.22M | $118.20M | — | -38.7% |
| Property, plant & equipment | — | — | — | — | $20.00K | — |
| Goodwill & intangibles | — | — | — | — | $0 | — |
| Total assets | $47.61M | $76.44M | $96.25M | $123.53M | — | -37.7% |
| Total current liabilities | $8.26M | $4.97M | $5.24M | $5.57M | — | +66.2% |
| Total debt | — | — | — | — | $0 | — |
| Total liabilities | $8.26M | $4.97M | $5.24M | $5.57M | — | +66.2% |
| Retained earnings | -$246.56M | -$211.79M | -$186.29M | -$156.19M | — | -16.4% |
| Shareholder equity | $39.35M | $71.48M | $91.02M | $117.96M | — | -44.9% |
| Working capital | $37.36M | $69.49M | $86.98M | $112.63M | — | -46.2% |
| Net tangible assets | $39.35M | $71.48M | $91.02M | $117.96M | — | -44.9% |
| Shares issued | 8.70M | 8.70M | 8.44M | 8.44M | — | +0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$34.77M | -$25.50M | -$30.09M | -$26.96M | -36.3% |
| Depreciation & amortisation | $16.00K | $17.00K | $23.00K | $8.00K | -5.9% |
| Stock-based compensation | $2.65M | $2.29M | $4.62M | $6.79M | +15.4% |
| Change in working capital | $2.35M | $448.00K | $1.52M | -$599.00K | +423.7% |
| Operating cash flow | -$29.76M | -$21.03M | -$20.94M | -$20.76M | -41.5% |
| Capital expenditure | -$23.00K | -$19.00K | -$14.00K | -$27.00K | -21.1% |
| Investing cash flow | -$23.00K | -$19.00K | -$14.00K | -$4.73M | -21.1% |
| Share buybacks | — | $0 | -$1.48M | $0 | — |
| Financing cash flow | $0 | $3.67M | -$1.48M | $0 | -100.0% |
| Free cash flow | -$29.79M | -$21.05M | -$20.95M | -$20.79M | -41.5% |
| End cash position | $41.41M | $71.19M | $88.57M | $111.00M | -41.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $4.90M | $4.78M | $6.16M | $5.37M | $5.50M | — | +2.5% |
| Selling, general & admin | $3.80M | $5.09M | $5.28M | $3.88M | $3.54M | — | -25.4% |
| Total operating expense | $8.69M | $9.87M | $11.44M | $9.25M | $9.04M | — | -11.9% |
| Operating income | -$8.69M | -$9.87M | -$11.44M | -$9.25M | -$9.04M | — | +11.9% |
| Net interest income | $227.00K | $309.00K | $442.00K | $570.00K | $645.00K | — | -26.5% |
| Pre-tax income | -$8.49M | -$9.59M | -$10.94M | -$8.69M | -$8.42M | — | +11.5% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — | — |
| Net income | -$8.49M | -$9.59M | -$10.94M | -$8.69M | -$8.42M | — | +11.5% |
| Net income to common | -$8.49M | -$9.59M | -$10.94M | -$8.69M | -$8.42M | — | +11.5% |
| Basic EPS | -0.95 | -1.11 | — | -1.05 | -0.98 | -0.75 | +14.4% |
| Diluted EPS | -0.95 | -1.11 | — | -1.05 | -0.98 | -0.75 | +14.4% |
| EBIT | -$8.69M | -$9.87M | -$11.44M | -$9.25M | -$9.04M | — | +11.9% |
| EBITDA | -$8.69M | -$9.87M | -$11.43M | -$9.25M | -$9.04M | — | +11.9% |
| Basic shares | 8.91M | 8.62M | — | 8.61M | 8.62M | 8.61M | +3.3% |
| Diluted shares | 8.91M | 8.62M | — | 8.61M | 8.62M | 8.61M | +3.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $26.09M | $31.72M | $41.30M | $51.84M | $57.86M | -17.7% |
| Cash & short-term investments | $26.09M | $31.72M | $41.30M | $51.84M | $57.86M | -17.7% |
| Total current assets | $31.01M | $36.67M | $45.62M | $55.68M | $62.52M | -15.4% |
| Total assets | $32.28M | $37.94M | $47.61M | $58.01M | $64.52M | -14.9% |
| Total current liabilities | $5.45M | $7.46M | $8.26M | $8.22M | $6.82M | -26.9% |
| Total liabilities | $5.45M | $7.46M | $8.26M | $8.22M | $6.82M | -26.9% |
| Retained earnings | -$264.64M | -$256.15M | -$246.56M | -$235.63M | -$226.93M | -3.3% |
| Shareholder equity | $26.83M | $30.49M | $39.35M | $49.79M | $57.70M | -12.0% |
| Working capital | $25.56M | $29.21M | $37.36M | $47.45M | $55.70M | -12.5% |
| Net tangible assets | $26.83M | $30.49M | $39.35M | $49.79M | $57.70M | -12.0% |
| Shares issued | 9.98M | 8.70M | 8.70M | 8.70M | 8.70M | +14.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$8.49M | -$9.59M | -$10.94M | -$8.69M | -$8.42M | — | +11.5% |
| Depreciation & amortisation | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | — | 0.0% |
| Stock-based compensation | $815.00K | $722.00K | $503.00K | $784.00K | $796.00K | — | +12.9% |
| Change in working capital | -$1.97M | -$718.00K | -$109.00K | $1.90M | $364.00K | — | -174.7% |
| Operating cash flow | -$9.64M | -$9.58M | -$10.54M | -$6.00M | -$7.26M | — | -0.7% |
| Capital expenditure | — | — | -$7.00K | -$7.00K | — | -$9.00K | — |
| Investing cash flow | $0 | $0 | -$7.00K | -$7.00K | $0 | — | — |
| Financing cash flow | $4.02M | $0 | $0 | $0 | $0 | — | — |
| Free cash flow | -$9.64M | -$9.58M | -$10.55M | -$6.01M | -$7.26M | — | -0.7% |
| End cash position | $26.20M | $31.83M | $41.41M | $51.95M | $57.97M | — | -17.7% |
Options analytics
Put / call volume
0.26
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
8.00
+226.5% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
19
Contracts, this expiry
Put volume
5
Contracts, this expiry
Heaviest call OI
1.00
0 contracts
Heaviest put OI
6.00
2 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.10 | -0.95 | +13.6% |
| Mar 2026 | -1.22 | -1.11 | +9.0% |
| Dec 2025 | -1.14 | -1.34 | -17.2% |
| Sep 2025 | -1.00 | -1.05 | -5.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.78 | 1 | $0 | 0.0% |
| Next quarter | -0.78 | 1 | $0 | 0.0% |
| Current year | -3.56 | 1 | $0 | 0.0% |
| Next year | -3.30 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$19.00
High target$25.00
Low target$10.00
Implied upside675.51%
Analyst count3
ConsensusSTRONG BUY
Strong buy / Buy1 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders1.85%
Held by institutions13.61%
Institutions holding40
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.15
+13.74% from price
SMA 20
2.26
+8.43% from price
SMA 50
2.39
+2.63% from price
SMA 100
2.81
-12.70% from price
SMA 200
4.61
-46.83% from price
EMA 12
2.26
+8.57% from price
EMA 26
2.30
+6.50% from price
EMA 50
2.44
+0.22% from price
RSI (14)
56.7
Neutral
MACD (12,26,9)
-0.04
Hist 0.04
ATR (14)
0.18
7.29% of price
Realised vol 30D
70.6%
Annualised
Bollinger upper
2.64
20, 2σ
Bollinger lower
1.88
20, 2σ
50 / 200 cross
Death
2.39 vs 4.61
Trend bias
Below 200
-46.83%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.08
More volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
70.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-90.1%
Peak to trough
Max drawdown 5Y
-96.4%
Peak to trough
ATR 14
0.18
7.29% of price
Beta (reported)
1.28
5Y monthly, from filing
Short interest
Shares short
762.16K
Prior 795.46K
Change vs prior
-4.2%
Shorts covering
% of float
7.64%
Normal
% of shares out
7.64%
Against total outstanding
Days to cover
14.0
Crowded exit
Float
9.94M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Jul 7, 26 | Rodman & Renshaw | INITIATED | — | Buy |
| Apr 10, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Mar 26, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 8, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Sep 22, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Jun 6, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Jun 5, 25 | Craig-Hallum | INITIATED | — | Buy |
| Apr 21, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Mar 26, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 12, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 30, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay dateApr 20, 2018
Last split1:15
Split dateFeb 2, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-29
Corporate Changes & Voting Matters
8-K · 2026-09-18
Corporate Changes & Voting Matters
8-K · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-06-11
Corporate Changes & Voting Matters
8-K · 2026-05-08
Corporate Changes & Voting Matters
8-K · 2026-04-16
Annual Report to Shareholders
ARS · 2026-03-30
Corporate Changes & Voting Matters
8-K · 2026-03-25
Headlines
Atossa plans shareholder stake in potential PRV proceeds
Pharmaceutical Technology · 7d ago
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
PR Newswire · 8d ago
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
PR Newswire · 13d ago
ATOS: Multiple Catalysts Converge in 2H26
Zacks Small Cap Research · 54d ago
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
PR Newswire · 61d ago
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
PR Newswire · 71d ago
Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run
Investor's Business Daily · 77d ago
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
PR Newswire · 78d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.